These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1718 related articles for article (PubMed ID: 12037682)

  • 21. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
    Zhang L; Kharbanda S; Hanfelt J; Kern FG
    Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
    Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
    Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
    Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.
    Migliaccio A; Piccolo D; Castoria G; Di Domenico M; Bilancio A; Lombardi M; Gong W; Beato M; Auricchio F
    EMBO J; 1998 Apr; 17(7):2008-18. PubMed ID: 9524123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
    Sabnis GJ; Jelovac D; Long B; Brodie A
    Cancer Res; 2005 May; 65(9):3903-10. PubMed ID: 15867390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
    Michalides R; Griekspoor A; Balkenende A; Verwoerd D; Janssen L; Jalink K; Floore A; Velds A; van't Veer L; Neefjes J
    Cancer Cell; 2004 Jun; 5(6):597-605. PubMed ID: 15193262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
    Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
    Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
    Berstein LM; Yue W; Wang JP; Santen RJ
    Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 86.